Journal of Neurology

, Volume 252, Issue 10, pp 1201–1205 | Cite as

Gender and the Parkinson’s disease phenotype

  • Y. Baba
  • J. D. Putzke
  • N. R. Whaley
  • Z. K. Wszolek
  • R. J. Uitti



To determine whether there are gender differences in the Parkinson’s disease (PD) phenotype using a large clinic–based cohort.


We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD.


The majority of individuals in the sample were male (67 %). Comparative analyses showed males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were about 70 and 63 years, respectively and, thus, disease duration was not significantly different between genders. The proportion of individuals with a positive family history of PD (15 %) was similar for both genders. A positive history of depression was significantly higher in females (35 % vs. 24 %). The UPDRS instability score was significantly worse among females, whereas the rigidity score was significantly worse for males. Females showed significantly worse ADL capacity and a more advanced H&Y stage. The proportion of individuals receiving antiparkinsonian medication (about 66 %) and time between the last dose and the clinical evaluation (about 4 hours) was similar for both genders. There was a trend for lower daily levodopa equivalence dosage and more severe dyskinesia score among females but these differences did not reach statistical significance after Bonferroni correction.


The majority of comparisons tended to highlight the commonalities in the PD phenotype between genders, particularly in reference to historical and early disease stage characteristics. However, gender may be an important factor related to the expression of PD features during the symptomatic disease course.

Key words

Parkinson’s disease gender clinical cohort demographic historical clinical characteristic 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E,Grigoletto F, Amaducci L, Inzitari D (2000) Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55:1358–1363PubMedGoogle Scholar
  2. 2.
    Becker JB (1999) Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 64:803–812PubMedGoogle Scholar
  3. 3.
    Bower JH, Maraganore DM, McDonnell SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County,Minnesota, 1976–1990. Neurology 52:1214–1220PubMedGoogle Scholar
  4. 4.
    Cummings JL, Masterman DL (1999) Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatry 14:711–718CrossRefPubMedGoogle Scholar
  5. 5.
    Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD (1990) An examination of male-female differences in progression and mortality of Parkinson’s disease. Neurology 40:763–766PubMedGoogle Scholar
  6. 6.
    Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM (1999) Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci 19:6385–6393PubMedGoogle Scholar
  7. 7.
    Fahn S, Elton RL, UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S,Marsden CD, Calne D,Goldstein M (eds) Recent developments in Parkinson’s disease, vol. 2. Macmillan Healthcare information, Florham Park, New York, pp 153–163Google Scholar
  8. 8.
    Green PS, Simpkins JW (2000) Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18:347–358PubMedGoogle Scholar
  9. 9.
    Hicks A, Petursson H, Jonsson T, Stefansson H, Johannsdottir H, Sainz J, Frigge ML, Kong A, Gulcher JR, Stefansson K, Sveinbjornsdottir S (2001) A susceptibility gene for late-onset idiopathic Parkinson’s disease successfully mapped. Am J Hum Genet 69 (Suppl):200Google Scholar
  10. 10.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442PubMedGoogle Scholar
  11. 11.
    Jankovic J, Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol 58:1611–1615CrossRefPubMedGoogle Scholar
  12. 12.
    Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB (1993) Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 29:85–96PubMedGoogle Scholar
  13. 13.
    Kuller LH, Gutai JP, Meilahn E, Matthews KA, Plantinga P (1990) Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women. Arteriosclerosis 10:1058–1066PubMedGoogle Scholar
  14. 14.
    Kuopio AM, Marttila RJ, Helenius H, Rinne UK (1999) Changing epidemiology of Parkinson’s disease in southwestern Finland. Neurology 52:302–308PubMedGoogle Scholar
  15. 15.
    Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56:334–337CrossRefPubMedGoogle Scholar
  16. 16.
    Marras C, Rochon P, Lang AE (2002) Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59:1724–1728CrossRefPubMedGoogle Scholar
  17. 17.
    Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, Tang MX, Lantigua R, Wilder D, Gurland B, et al. (1995) The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 142:820–827PubMedGoogle Scholar
  18. 18.
    McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal function. Arch Neurol 34:33–35PubMedGoogle Scholar
  19. 19.
    Milanov I, Kmetska K, Karakolev B, Nedialkov E (2001) Prevalence of Parkinson’s disease in Bulgaria. Neuroepidemiology 20:212–214CrossRefPubMedGoogle Scholar
  20. 20.
    Miller DB, Ali SF, O’Callaghan JP, Laws SC (1998) The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 844:153–165PubMedGoogle Scholar
  21. 21.
    Nishizawa S, Benkelfat C,Young SN, Leyton M, Mzengeza S, de Montigny C, Blier P, Diksic M (1997) Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94:5308–5313CrossRefPubMedGoogle Scholar
  22. 22.
    Okun MS, Watts RL (2002) Depression associated with Parkinson’s disease: clinical features and treatment. Neurology 58(Suppl 1):S63–S70PubMedGoogle Scholar
  23. 23.
    Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T; Parkinson Study Group (2002) Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 71:124–135CrossRefPubMedGoogle Scholar
  24. 24.
    Parkinson study group (1989) DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46:1052–1060PubMedGoogle Scholar
  25. 25.
    Sawada H, Ibi M, Kihara T, Honda K, Nakamizo T, Kanki R, Nakanishi M, Sakka N, Akaike A, Shimohama S (2002) Estradiol protects dopaminergic neurons in a MPP+ Parkinson’s disease model. Neuropharmacology 42:1056–1064CrossRefPubMedGoogle Scholar
  26. 26.
    Sawada H, Shimohama S (2000) Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci Biobehav Rev 24:143–147CrossRefPubMedGoogle Scholar
  27. 27.
    Schrag A, Ben-Shlomo Y, Quinn NP (2000) Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ 321:21–22CrossRefPubMedGoogle Scholar
  28. 28.
    Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM (2000) Gender differences in Parkinson’s disease symptom profile. Acta Neurol Scand 102:37–43CrossRefPubMedGoogle Scholar
  29. 29.
    Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Slotterbeck B, Booze MW, Ribble RC, Rampersaud E, West SG, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Vance JM, Pericak-Vance MA (2001) Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286:2239–2244CrossRefPubMedGoogle Scholar
  30. 30.
    Tom T, Cummings JL (1998) Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs Aging 12:55–74PubMedGoogle Scholar
  31. 31.
    Uitti RJ, Baba Y, Tsuboi Y, Strongosky AJ, Wszolek ZK, Putzke JD (2004) Asymmetry of Parkinson’s disease: the influence of handedness. Mov Disord 19(Suppl 9):S196CrossRefGoogle Scholar
  32. 32.
    Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022PubMedGoogle Scholar
  33. 33.
    Van Hartesveldt C, Joyce JN (1986) Effects of estrogen on the basal ganglia. Neurosci Biobehav Rev 10:1–14CrossRefPubMedGoogle Scholar
  34. 34.
    Veliskova J, Moshe SL (2001) Sexual dimorphism and developmental regulation of substantia nigra function. Ann Neurol 50:596–601CrossRefPubMedGoogle Scholar
  35. 35.
    Walker QD, Rooney MB, Wightman RM, Kuhn CM (2000) Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry. Neuroscience 95:1061–1070CrossRefPubMedGoogle Scholar
  36. 36.
    Ward CD, Gibb WR (1990) Research diagnostic criteria for Parkinson’s disease. Adv Neurol 53:245–249PubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2005

Authors and Affiliations

  • Y. Baba
    • 1
  • J. D. Putzke
    • 1
  • N. R. Whaley
    • 1
  • Z. K. Wszolek
    • 1
  • R. J. Uitti
    • 1
  1. 1.Dept. of NeurologyMayo Clinic JacksonvilleJacksonville (FL) 32224USA

Personalised recommendations